Distinct lipid changes in primary biliary cholangitis may signal inflammation and fibrosis. Discover how these findings could ...

Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct stricturing, which ultimately leads to cirrhosis and liver failure. PSC is ...

In this video, Marlyn Mayo, MD, discusses “revealing” data from the eMPower trial that showed a digital mind-body wellness program improved mental health and fatigue in primary sclerosing cholangitis ...

Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec ...

Twenty-five centers across six Asian countries collaborated in the first large-scale study on primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease, in patients with inflammatory ...

The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...

FOSTER CITY, Calif., October 23, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with ...

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline ...

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...